BeiGene Announces Clinical Data on Tislelizumab and Zanubrutinib to be Presented at the 24th Congress of the European Hematology Association

NEXT STORY
Forty Seven, Inc. to Present Updated Data from Ongoing Phase 1b/2 Clinical Trial of 5F9 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma at 24th Congress of the European Hematology Association
PREV STORY
Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

A new study comparing TK 210™ ELISA from AroCell with other activity-based assays for the measurement of TK1 in serum shows high correlation between methods when samples from subjects with hematological malignancies are compared. The study

An abstract entitled “A performance evaluation of three currently used thymidine kinase 1 assays ...

author_avatar
NASDAQ Market News

Inovio Doses 1st Subject in Phase 1/2 Clinical Trial For Vaccine Against Deadly MERS Infection

PLYMOUTH MEETING, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) ...

author_avatar
NASDAQ Market News

Global Companion Diagnostics Market to Reach a New Threshold of Growth: Expected to Reach USD 7.8 Billion in 2027

author_avatar
NASDAQ Market News